Skip to main content
Glama

Search BPDR Annual Summary

fda_bpdr_summary
Read-onlyIdempotent

Search FDA's Biological Product Deviation Report annual summary counts. This is summary-level biotech and blood/HCT/P manufacturing signal from official FDA annual reports, not per-event case detail.

Input Schema

TableJSON Schema
NameRequiredDescriptionDefault
limitNoMax results to return (1-500)
offsetNoResult offset for pagination
keywordNoKeyword to search in group_name or establishment_type
row_typeNoWhether the row is a normal establishment line, subtotal, or total
group_nameNoGroup name, for example Licensed Non-Blood Manufacturers
fiscal_yearNoMetric fiscal year, for example 2024
establishment_typeNoEstablishment type, for example Vaccine or 351 HCT/P

TDQS

A4/5.0
Behavior3/5

Does the description disclose side effects, auth requirements, rate limits, or destructive behavior?

Annotations already declare readOnlyHint=true and idempotentHint=true, so the safety profile is known. The description adds the key context that results are aggregate annual summary counts from official reports, not detailed case-level data. This is useful but minimal; no additional behavioral traits like pagination behavior or data freshness are disclosed.

Agents need to know what a tool does to the world before calling it. Descriptions should go beyond structured annotations to explain consequences.

Conciseness5/5

Is the description appropriately sized, front-loaded, and free of redundancy?

The description is two sentences with no fluff. The first sentence front-loads the exact action and resource, and the second adds essential scope clarification. Every word earns its place.

Shorter descriptions cost fewer tokens and are easier for agents to parse. Every sentence should earn its place.

Completeness4/5

Given the tool's complexity, does the description cover enough for an agent to succeed on first attempt?

Given the 7 optional parameters, full schema coverage, and helpful annotations, the description provides enough context: the data source, granularity, and topic area. It lacks an explicit return-value structure, but the lack of an output schema is mitigated by the clear 'summary counts' phrasing. A brief note on return format would make it fully complete.

Complex tools with many parameters or behaviors need more documentation. Simple tools need less. This dimension scales expectations accordingly.

Parameters3/5

Does the description clarify parameter syntax, constraints, interactions, or defaults beyond what the schema provides?

The input schema covers 100% of parameters with descriptions, so the baseline is 3. The tool description does not add any extra parameter-level meaning beyond what the schema already provides, so the score stays at the baseline.

Input schemas describe structure but not intent. Descriptions should explain non-obvious parameter relationships and valid value ranges.

Purpose5/5

Does the description clearly state what the tool does and how it differs from similar tools?

The description clearly states the tool searches for FDA's Biological Product Deviation Report annual summary counts, using specific verbs and resource names. It also distinguishes from per-event case detail, which uniquely identifies its scope among the many FDA search tools.

Agents choose between tools based on descriptions. A clear purpose with a specific verb and resource helps agents select the right tool.

Usage Guidelines4/5

Does the description explain when to use this tool, when not to, or what alternatives exist?

The description provides clear context on data granularity (summary-level vs. per-event) and explicitly notes what the tool does not do ('not per-event case detail'). However, it does not name an alternative tool for per-event searches, so it stops short of the explicit alternative guidance that would earn a 5.

Agents often have multiple tools that could apply. Explicit usage guidance like "use X instead of Y when Z" prevents misuse.

Try in Browser

Glama MCP Gateway

Add one secure layer between your agents and this server.

TDQS

A4.1/5.0
Disambiguation4/5

Most tools have distinct purposes with clear boundaries, such as fda_search_drugs for drug applications and fda_search_510k for device clearances. However, some overlap exists, like fda_device_udi and fda_device_udi_lookup both querying UDI data, which could cause confusion despite differences in scope.

Naming Consistency5/5

All tool names follow a consistent snake_case pattern with a clear fda_ prefix, using descriptive verbs like search, get, list, and link. This uniformity makes the set predictable and easy to navigate, with no deviations in naming style.

Tool Count2/5

With 48 tools, the count is excessive for a single server, making it overwhelming and difficult for agents to manage. While the domain is broad (FDA data), the toolset feels bloated with many specialized or overlapping tools that could be consolidated.

Completeness5/5

The toolset provides comprehensive coverage of FDA data domains, including drugs, devices, inspections, compliance, recalls, and facilities. It supports full CRUD-like operations (e.g., search, get, link, save) and lifecycle workflows, with no obvious gaps for the intended purpose.

Resources